Mode
Text Size
Log in / Sign up

Early exclusive enteral feeding does not increase necrotizing enterocolitis risk in preterm infantsEarly Enteral Feeding Shows No Increased Risk of Necrotizing Enterocolitis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that early exclusive enteral feeding (within 48 hours) does not increase necrotizing enterocolitis risk in preterm infants.

This meta-analysis evaluated the safety and efficacy of early exclusive enteral feeding (EEF) initiated within 48 hours of birth compared to progressive enteral feeding (PEF) in preterm infants (27+0 to 36+0 weeks). The study included a total of 3,145 infants to assess outcomes including necrotizing enterocolitis (NEC), hypoglycemia, and sepsis.

The meta-analysis found no significant difference between EEF and PEF regarding the incidence of NEC stage 2 or greater (RR 1.00; 95% CI, 1.00-1.01; P =.53), hypoglycemia (RR 1.00; 95% CI, 0.98-1.02; P =.80), or culture-proven sepsis (RR 1.03; 95% CI, 1.00-1.07; P =.08). However, EEF was associated with a significantly shorter time to full feeds, reduced duration of intravenous fluids, faster regain of birth weight, and shorter hospital stays.

Limitations noted by the authors include statistical heterogeneity in some outcomes and a lack of blinding in interventions. The certainty of evidence for any NEC is moderate, while the certainty for other outcomes is low to very low. Clinical practice relevance suggests that EEF appears feasible and does not increase NEC risk, though larger trials are needed to confirm safety and assess long-term outcomes.

How this fits prior evidence

This meta-analysis addresses a gap in clinical management by evaluating early enteral feeding protocols. It confirms that early exclusive enteral feeding does not increase the risk of necrotizing enterocolitis, a condition also associated with traditional Tibetan feeding practices. Furthermore, it provides a safety profile for early feeding that complements the finding that early postnatal antibiotic exposure is associated with higher risk of both BPD and NEC in very preterm infants.

Researchers analyzed data from over 3,000 preterm infants to compare two feeding methods. One method involved early exclusive enteral feeding (EEF) starting within 48 hours of birth, while the other used progressive enteral feeding (PEF). The goal was to see if starting enteral feeds early affected the risk of necrotizing enterocolitis (NEC), a serious intestinal condition.

The study found that early enteral feeding did not increase the risk of NEC, hypoglycemia, or culture-proven sepsis compared to the standard method. However, infants who received early enteral feeding reached full feeds faster, regained birth weight more quickly, and had shorter durations of intravenous fluids. They also spent less time in the hospital.

Because this was a meta-analysis, the results are based on existing data rather than a single new trial. While the findings suggest that early enteral feeding is a feasible option, the evidence for many specific outcomes is considered low to very low certainty. More large, well-designed trials are needed to confirm these safety results and look at long-term outcomes.

What this means for you:
Early enteral feeding may help preterm infants gain weight faster without increasing the risk of NEC.

Common questions

Does early enteral feeding increase the risk of NEC?

The study found no significant difference in the incidence of necrotizing enterocolitis (NEC) stage 2 or greater between early enteral feeding and progressive enteral feeding. This suggests that starting enteral feeds within 48 hours of birth does not appear to increase the risk of this condition in preterm infants.

How does early enteral feeding affect weight gain?

Infants who received early enteral feeding showed a faster regain of birth weight compared to those who received progressive enteral feeding. This suggests that the early feeding method may help infants gain weight more quickly after birth.

Are there other benefits to early enteral feeding?

The study found that infants receiving early enteral feeding reached full feeds in a significantly shorter amount of time. These infants also had a shorter duration of intravenous fluids and shorter overall hospital stays.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up0.0 mo
PublishedSep 2026
View Original Abstract ↓
CONTEXT: Early exclusive enteral feeding (EEF) in preterm infants may provide advantages such as improved nutritional delivery, reduced need for intravenous fluids (IVF), and lower health care costs. However, concerns persist regarding adverse outcomes, particularly necrotizing enterocolitis (NEC). OBJECTIVE: To determine if EEF compared with progressive enteral feed (PEF) is associated with benefits without causing any adverse effects. DATA SOURCES: MEDLINE, EMBASE, EMCARE, CINAHL, Cochrane Library, and clinical trial registries from inception to October 2025. STUDY SELECTION: Randomized controlled trials comparing EEF commenced within 48 hours of birth with PEF in preterm infants. DATA EXTRACTION: Two authors independently extracted data on clinical outcomes of interest using a standardized data collection form. RESULTS: Eleven studies (n = 3145) were included (27+0 to 36+0 weeks). No significant differences were observed in the incidence of NEC stage 2 or greater (pooled relative risk [RR], 1.00; 95% CI, 1.00-1.01; P = .53), hypoglycemia (pooled RR, 1.00; 95% CI, 0.98-1.02; P = .80), or culture-proven sepsis (pooled RR, 1.03; 95% CI, 1.00-1.07; P = .08). EEF was associated with significantly shorter time to full feeds, reduced duration of IVF, faster regain of birth weight, and shorter hospital stay. Certainty of evidence (COE) was moderate for "any NEC" and low to very low for other outcomes. LIMITATIONS: Presence of statistical heterogeneity in some outcomes and lack of blinding in interventions. CONCLUSIONS: EEF appears to be feasible. Based on moderate COE, it does not appear to increase the risk of NEC. Larger and well-designed trials across diverse settings are needed to confirm its safety, evaluate potential benefits-including cost, and assess long-term outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.